A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Chunyin, Cao, Xiaodan, Wang, Zongda, Hu, Xue, Yao, Yanfeng, Zhou, Yiwu, Liu, Peipei, Liu, Xiaowu, Gao, Ge, Hu, Xiao, Zhang, Yecheng, Chen, Zhen, Gao, Li, Peng, Yun, Jia, Fangfang, Shan, Chao, Yu, Li, Liu, Kunpeng, Li, Nan, Guo, Weiwei, Jiang, Guoping, Min, Juan, Zhang, Jianjian, Yang, Lu, Shi, Meng, Hou, Tianquan, Li, Yanan, Liang, Weichen, Lu, Guoqiao, Yang, Congyi, Wang, Yuting, Xia, Kaiwen, Xiao, Zheng, Xue, Jianhua, Huang, Xueyi, Chen, Xin, Ma, Haixia, Song, Donglin, Pan, Zhongzong, Wang, Xueping, Guo, Haibing, Liang, Hong, Yuan, Zhiming, Guan, Wuxiang, Deng, Su-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189090/
https://www.ncbi.nlm.nih.gov/pubmed/34097570
http://dx.doi.org/10.1080/19420862.2021.1930636
Descripción
Sumario:Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein during infection. After the virus sequence was published, we identified two potent antibodies against the SARS-CoV-2 receptor binding domain (RBD) from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a Phase 1 clinical trial (ChiCTR2100042150), showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.

Ejemplares similares